Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Santarus proposes follow-on

SNTS plans to sell 6 million shares in a follow-on underwritten by SG

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE